Title: Evaluation of Clinical Usage of Partial Dopamine Receptor Agonist
Abstract: OBJECTIVE:To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application. METHODS: By reviewing recent literatures at home and abroad and writing about research progress and clinical trial of p artial dopamine receptor agonist. RESULTS CONCLUSION: Partial dopamine recep tor agonist is effective and safe for schizophrenia. Development of aripiprazole with partial agonist activity at both D 2 and 5-HT 1A receptors has confi rmed the value of the partial agonist in the treatment of schizophrenia. Compared with placebo,aripiprazole shows more efficient for positive and negative symptoms, i ts efficiency is corresponding to that of haloperidol and risperidone. In additi on, its safety and tolerance are quite good ,seldom causes rising of the level s of EPS and prolactin.
Publication Year: 2005
Publication Date: 2005-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot